Paper Details

  1. Home
  2. Paper Details

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.

Author: AkkermansReinier P, LucassenPeter L, RuttenGuy E, van WeelChris, van de LaarFloris A, van de LisdonkEloy H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Alpha-glucosidase inhibitors (AGIs) have no effect on mortality or morbidity in patients with type 2 diabetes. AGIs have clear beneficial effects on glycemic control and postload insulin levels, but not on plasma lipids. Dosages higher than 50 mg acarbose three times daily are not necessary.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To review the effects of monotherapy with alpha-glucosidase inhibitors (AGIs) for patients with type 2 diabetes, with respect to mortality, morbidity, glycemic control, insulin levels, plasma lipids, body weight, and side effects. RESEARCH DESIGN AND METHODS: We systematically searched t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2337/diacare.28.1.154

データ提供：米国国立医学図書館（NLM）

Alpha-Glucosidase Inhibitors: A Promising Approach for Type 2 Diabetes

Type 2 diabetes is a chronic disease that affects millions of people worldwide. This Cochrane systematic review and meta-analysis evaluate the effectiveness of alpha-glucosidase inhibitors (AGIs), a class of drugs that delay carbohydrate absorption, in managing type 2 diabetes. The authors analyzed 41 randomized controlled trials comparing AGI monotherapy with various interventions.

AGIs Demonstrate Benefits for Glycemic Control

The meta-analysis revealed that AGIs, compared to placebo, had a beneficial effect on HbA1c levels, fasting and postload blood glucose, and postload insulin levels. These findings indicate that AGIs can effectively improve glycemic control in patients with type 2 diabetes.

Navigating the Desert of Diabetes Management

This review underscores the importance of individualized treatment approaches for type 2 diabetes. While AGIs can be a valuable tool, it's important to consider individual patient characteristics, potential side effects, and effectiveness in achieving therapeutic goals. Like a camel navigating a diverse desert landscape, healthcare providers must adapt treatment strategies to meet each patient's unique needs.

Dr.Camel's Conclusion

The desert of type 2 diabetes management can be a challenging one, but this review suggests that AGIs can be a valuable resource in controlling blood sugar levels. It reminds us that the pursuit of effective diabetes management requires a thorough understanding of different treatment options and a commitment to individualized care.

Date :
  1. Date Completed 2005-05-24
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

15616251

DOI: Digital Object Identifier

10.2337/diacare.28.1.154

Related Literature

Article Analysis
・Side Effects of miglitol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.